These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 7996395)
1. Pharmacokinetic behaviour in polymorphonuclear leucocytes of N,N-dimethylcarbamoylmethyl alpha,2-dimethyl-5H-[1]benzopyrano[2,3-b]- pyridine-7-acetate (Y-23023), a new prodrug type of anti-inflammatory agent, and indomethacin after oral administrations in rats. Yamada I; Nagamatsu Y; Imayoshi T; Shibata M; Tsuji A J Pharm Pharmacol; 1994 Jul; 46(7):614-6. PubMed ID: 7996395 [TBL] [Abstract][Full Text] [Related]
2. Effect of gastric acidity on bioavailability of N,N-dimethylcarbamoylmethylalpha, 2-dimethyl-5H-[1]benzopyrano[2,3-b]pyridine-7-acetate, a new prodrug-type anti-inflammatory agent. Yamada I; Goda T; Kawata M; Mizuta H; Ogawa K; Yokobe T Chem Pharm Bull (Tokyo); 1989 Dec; 37(12):3372-5. PubMed ID: 2632086 [TBL] [Abstract][Full Text] [Related]
3. [Synthesis, pharmacological activity and biopharmaceutical characteristics of alpha,2-dimethyl-5H-[1]benzopyrano[2,3-b]pyridine-7-acetates]. Kawasaki K; Yamada I; Oe T; Tsuruda M; Terasawa M; Imayoshi T; Yasunaga Y; Goto K Yakugaku Zasshi; 1989 Nov; 109(11):827-34. PubMed ID: 2614665 [TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic and pharmacodynamic profile of the trioxyethylene ester of indomethacin in a new oral prodrug]. Palagiano F; de Caprariis P; Bonina FP; Montenegro L; Capasso A; Sorrentino L Boll Chim Farm; 1996 Feb; 135(2):89-91. PubMed ID: 9044565 [No Abstract] [Full Text] [Related]
5. Pharmacokinetic evaluation of indomethacin ethyl ester-loaded nanoencapsules. Cattani VB; Pohlmann AR; Dalla Costa T Int J Pharm; 2008 Nov; 363(1-2):214-6. PubMed ID: 18678236 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of a novel, long-acting, prodrug-type potassium channel opener, Y-27152, in healthy volunteers. Uematsu T; Kosuge K; Hirosawa S; Kadobe Y; Hibi T; Nakashima M J Clin Pharmacol; 1996 May; 36(5):439-51. PubMed ID: 8739023 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of indomethacin ester prodrugs: gastrointestinal and hepatic toxicity and the hydrolytic capacity of various tissues in rats. Ogiso T; Iwaki M; Tanino T; Nagai T; Ueda Y; Muraoka O; Tanabe G Biol Pharm Bull; 1996 Sep; 19(9):1178-83. PubMed ID: 8889037 [TBL] [Abstract][Full Text] [Related]
8. Enhanced transdermal absorption and pharmacokinetic evaluation of pranoprofen-ethylene-vinyl acetate matrix containing penetration enhancer in rats. Cho CW; Choi JS; Yang KH; Shin SC Arch Pharm Res; 2009 May; 32(5):747-53. PubMed ID: 19471890 [TBL] [Abstract][Full Text] [Related]
9. Transdermal delivery of indomethacin by iontophoresis. Kanebako M; Inagi T; Takayama K Biol Pharm Bull; 2002 Jun; 25(6):779-82. PubMed ID: 12081146 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of indomethacin octyl ester (prodrug) and indomethacin produced from the prodrug. Ogiso T; Iwaki M; Kinoshita T; Tanino T; Paku T J Pharm Sci; 1994 Jan; 83(1):34-7. PubMed ID: 8138906 [TBL] [Abstract][Full Text] [Related]
11. [Analgesic and anti-inflammatory effect of (+/-)-N,N- dimethylcarbamoylmethyl 2-[7-(2-methyl-5H-[1] benzopyrano [2,3-b] pyridyl)] propionate (Y-23023), a new non-steroidal anti-inflammatory drug]. Iwahisa Y; Yasunaga Y; Ochi H; Matsuura M; Imayoshi T; Terasawa M Nihon Yakurigaku Zasshi; 1995 Aug; 106(2):99-111. PubMed ID: 7557742 [TBL] [Abstract][Full Text] [Related]
12. A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated, lower-dose oral indomethacin. Manvelian G; Daniels S; Altman R Postgrad Med; 2012 Jul; 124(4):197-205. PubMed ID: 22913908 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. Lee SD; Lee WI; Shim HJ; Lee ED; Kim WB; Yang J; Kim CK; Lee MG J Clin Pharm Ther; 1996 Aug; 21(4):201-13. PubMed ID: 8933293 [TBL] [Abstract][Full Text] [Related]
14. Enhanced absorption of indomethacin after oral or rectal administration of a self-emulsifying system containing indomethacin to rats. Kim JY; Ku YS Int J Pharm; 2000 Jan; 194(1):81-9. PubMed ID: 10601687 [TBL] [Abstract][Full Text] [Related]
15. [Dissolution properties and bioavailability of ground mixture of N,N-dimethylcarbamoylmethyl alpha, 2-dimethyl-5H-[1]benzopyrano[2,3-b]-pyridine-7-acetate with various pharmaceutical ingredients]. Yamada I; Kawata M; Shibata T; Ogawa K; Yokobe T Yakugaku Zasshi; 1989 Dec; 109(12):932-7. PubMed ID: 2630636 [TBL] [Abstract][Full Text] [Related]
16. Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. Chae KA; Cho HJ; Sung JM; Lee H; Seo DC; Kim JS; Shin HC J Vet Sci; 2007 Sep; 8(3):263-7. PubMed ID: 17679773 [TBL] [Abstract][Full Text] [Related]
17. A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. Maya MT; Pais JP; Ruas Da Silva J; Morais JA Eur J Drug Metab Pharmacokinet; 1995; 20(4):275-9. PubMed ID: 8983932 [TBL] [Abstract][Full Text] [Related]
18. Effect of food on systemic exposure to niflumic acid following postprandial administration of talniflumate. Kang W; Kim K; Kim EY; Kwon KI; Bang JS; Yoon YR Eur J Clin Pharmacol; 2008 Oct; 64(10):1027-30. PubMed ID: 18607579 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacological studies of 2-(5H-(1)benzopyrano[2,3-b]pyridin-7-yl)propionic acid (Y-8004). (3) Its interaction with anti-inflammatory agents]. Maruyama Y; Imayoshi T; Foto K; Kadobe Y Nihon Yakurigaku Zasshi; 1977 Jan; 73(1):113-22. PubMed ID: 558941 [TBL] [Abstract][Full Text] [Related]
20. Plasma and cerebrospinal fluid concentrations of indomethacin in children after intravenous administration. Mannila A; Kumpulainen E; Lehtonen M; Heikkinen M; Laisalmi M; Salo T; Rautio J; Savolainen J; Kokki H J Clin Pharmacol; 2007 Jan; 47(1):94-100. PubMed ID: 17192507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]